VEGF 165 (AA 27-191) (Active) Protein
-
- Target
- VEGF 165
- Protein Type
- Recombinant
- Biological Activity
- Active
- Protein Characteristics
- AA 27-191
-
Origin
- Human
-
Source
- HEK-293T Cells
- Characteristics
- ED50 <16 ng/mL, measured in a cell proliferation assay using HUVEC cells.
- Purity
- > 95 % as analyzed by SDS-PAGE.
- Endotoxin Level
- < 0.2 EU/μg, determined by LAL method.
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Reconstituted in ddH2O or PBS at 100 μg/mL.
- Buffer
- Lyophilized after extensive dialysis against PBS.
- Storage
- -80 °C
- Storage Comment
- Lyophilized recombinant Human Vascular Endothelial Growth Factor 165 (VEGF-165) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, Human Vascular Endothelial Growth Factor 165 (VEGF-165) should be stable up to 1 week at 4°C or up to 2 months at -20°C.
- Expiry Date
- 6 months
-
- Target
- VEGF 165
- Alternative Name
- Vascular Endothelial Growth Factor 165 (VEGF165)
- Background
-
Vascular Endothelial Growth Factor is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors, fms-like tyrosine kinase (flt-1), KDR gene product (the mouse homolog of KDR is the flk-1 gene product) and the flt4 gene product.
Synonyms: Vascular Endothelial Growth Factor, VPF, Folliculostellate cell-derived growth factor, Glioma-derived endothelial cell mitogen - Molecular Weight
- 20-26 kDa, observed by reducing SDS-PAGE.
- NCBI Accession
- NP_001165097
-